Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Covid-19

Thumbnail
April 08, 2021

Astra counts the cost of its Covid-19 vaccine

The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.

Thumbnail
April 07, 2021

Biotech venture financing starts the year with a bang

With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.

Thumbnail
April 08, 2021

Astra counts the cost of its Covid-19 vaccine

The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.

Thumbnail
April 07, 2021

Biotech venture financing starts the year with a bang

With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.

Article image
Vantage logo
March 31, 2021

Pfizer’s Covid paediatric jab needs to win in the home as well as the clinic

Article image
Vantage logo
March 29, 2021

Humanigen claims a Covid-19 win with lenzilumab

But the company focused on a modified intent-to-treat analysis of its pivotal trial.

Article image
Vantage logo
March 25, 2021

Astra’s Covid-19 vaccine: much ado about nothing?

With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.

Article image
Vantage logo
March 24, 2021

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

Article image
Vantage logo
March 23, 2021

Obfuscation and evasion: Astra shows how not to disclose data

The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.

Article image
Vantage logo
March 22, 2021

Astrazeneca silences its Covid-19 vaccine doubters

AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.

Article image
Vantage logo
March 18, 2021

Biofire lights the way with Covid-19 test de novo

Article image
Vantage logo
March 16, 2021

Covid-19 variant tests emerge – but only for research

Article image
Vantage logo
March 15, 2021

Roche buys Genmark for Covid-19 tests and more

At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Article image
Vantage logo
March 31, 2021

Pfizer’s Covid paediatric jab needs to win in the home as well as the clinic

Article image
Vantage logo
March 29, 2021

Humanigen claims a Covid-19 win with lenzilumab

But the company focused on a modified intent-to-treat analysis of its pivotal trial.

Article image
Vantage logo
March 25, 2021

Astra’s Covid-19 vaccine: much ado about nothing?

With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.

Article image
Vantage logo
March 24, 2021

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

Article image
Vantage logo
March 23, 2021

Obfuscation and evasion: Astra shows how not to disclose data

The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.

Article image
Vantage logo
March 22, 2021

Astrazeneca silences its Covid-19 vaccine doubters

AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.

Article image
Vantage logo
March 18, 2021

Biofire lights the way with Covid-19 test de novo

Article image
Vantage logo
March 16, 2021

Covid-19 variant tests emerge – but only for research

Article image
Vantage logo
March 15, 2021

Roche buys Genmark for Covid-19 tests and more

At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.